Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Allena Pharmaceuticals Inc (ALNA)

Allena Pharmaceuticals Inc (ALNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,288
  • Shares Outstanding, K 38,291
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,340 K
  • 60-Month Beta 2.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.15
Trade ALNA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.18
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.22
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +59.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3100 +12.21%
on 03/05/21
2.2400 -34.38%
on 02/09/21
-0.5600 (-27.59%)
since 02/05/21
3-Month
1.2100 +21.49%
on 12/23/20
2.7800 -47.12%
on 01/26/21
+0.1800 (+13.95%)
since 12/04/20
52-Week
0.5250 +180.00%
on 03/16/20
3.3900 -56.64%
on 06/03/20
-0.4600 (-23.83%)
since 03/05/20

Most Recent Stories

More News
Thinking about buying stock in Gamida Cell, Co-Diagnostics, T2 Biosystems, FSD Pharma, or Allena Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMDA, CODX, TTOO, HUGE, and ALNA.

ALNA : 1.4700 (-2.00%)
GMDA : 8.30 (-1.54%)
HUGE : 1.6900 (-5.06%)
TTOO : 1.6000 (-17.95%)
CODX : 12.34 (-6.52%)
Thinking about buying stock in Phio Pharmaceuticals, Allena Pharmaceuticals, Aemetis, Atossa Therapeutics, or Heat Biologics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHIO, ALNA, AMTX, ATOS, and HTBX.

ALNA : 1.4700 (-2.00%)
AMTX : 12.16 (-11.88%)
PHIO : 2.53 (unch)
ATOS : 2.23 (+4.21%)
HTBX : 7.68 (-2.91%)
Allena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the Upgrade

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ALNA : 1.4700 (-2.00%)
Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?

Is (ALNA) Outperforming Other Medical Stocks This Year?

ALNA : 1.4700 (-2.00%)
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and...

ALNA : 1.4700 (-2.00%)
Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and...

ALNA : 1.4700 (-2.00%)
Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and...

ALNA : 1.4700 (-2.00%)
Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346

-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated --

ALNA : 1.4700 (-2.00%)
Allena Pharmaceuticals to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and...

ALNA : 1.4700 (-2.00%)
Allena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

/p>

ALNA : 1.4700 (-2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which...

See More

Key Turning Points

3rd Resistance Point 1.7833
2nd Resistance Point 1.6567
1st Resistance Point 1.5633
Last Price 1.4700
1st Support Level 1.3433
2nd Support Level 1.2167
3rd Support Level 1.1233

See More

52-Week High 3.3900
Fibonacci 61.8% 2.2956
Fibonacci 50% 1.9575
Fibonacci 38.2% 1.6194
Last Price 1.4700
52-Week Low 0.5250

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar